Compare Stocks: LITS, NAKA, HSDT, and UPXI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HSDT Solana	$2.29 -0.4%	$1.91	$1.18 ▼ $25.50	$138.45M	1.06	354,527 shs	489,694 shs
LITS Lite Strategy	$1.04 +2.0%	$0.99	$0.69 ▼ $2.97	$35.39M	0.21	341,680 shs	904,978 shs
NAKA KindlyMD	$8.50 +3.7%	$5.86	$3.33 ▼ $62.00	$152.15M	15.99	198,167 shs	222,005 shs
UPXI Upexi	$1.06 +0.5%	$0.91	$0.54 ▼ $7.75	$83.03M	-0.21	3.72 million shs	3.79 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HSDT Solana	+4.07%	+4.55%	+38.55%	+41.98%	-89.70%
LITS Lite Strategy	-6.42%	-3.77%	+15.90%	+23.22%	+101,999,900.00%
NAKA KindlyMD	+5.40%	+2.76%	+63.02%	+94.77%	-86.33%
UPXI Upexi	+1.94%	+1.45%	+31.41%	+15.69%	-81.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HSDT Solana	$2.29 -0.4%	$1.91	$1.18 ▼ $25.50	$138.45M	1.06	354,527 shs	489,694 shs
LITS Lite Strategy	$1.04 +2.0%	$0.99	$0.69 ▼ $2.97	$35.39M	0.21	341,680 shs	904,978 shs
NAKA KindlyMD	$8.50 +3.7%	$5.86	$3.33 ▼ $62.00	$152.15M	15.99	198,167 shs	222,005 shs
UPXI Upexi	$1.06 +0.5%	$0.91	$0.54 ▼ $7.75	$83.03M	-0.21	3.72 million shs	3.79 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HSDT Solana	+4.07%	+4.55%	+38.55%	+41.98%	-89.70%
LITS Lite Strategy	-6.42%	-3.77%	+15.90%	+23.22%	+101,999,900.00%
NAKA KindlyMD	+5.40%	+2.76%	+63.02%	+94.77%	-86.33%
UPXI Upexi	+1.94%	+1.45%	+31.41%	+15.69%	-81.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HSDT Solana	2.40	Hold	$3.75	64.11% Upside
LITS Lite Strategy	1.00	Sell	N/A	N/A
NAKA KindlyMD	2.40	Hold	$19.33	132.09% Upside
UPXI Upexi	2.00	Hold	$5.00	373.93% Upside

Current Analyst Ratings Breakdown

Latest LITS, NAKA, HSDT, and UPXI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1.30 ➝ $2.00
9/8/2026	LITS Lite Strategy	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/4/2026	UPXI Upexi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/3/2026	HSDT Solana	B Riley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/3/2026	HSDT Solana	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$2.50 ➝ $3.50
9/3/2026	NAKA KindlyMD	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.00 ➝ $11.00
8/21/2026	LITS Lite Strategy	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	HSDT Solana	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$3.00 ➝ $2.50
8/7/2026	NAKA KindlyMD	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/6/2026	LITS Lite Strategy	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/27/2026	NAKA KindlyMD	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1.00 ➝ $17.00

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HSDT Solana	$6.02M	22.95	N/A	N/A	$6.88 per share	0.33
LITS Lite Strategy	$65.30M	0.55	$5.86 per share	0.18	N/A	∞
NAKA KindlyMD	$1.82M	81.93	N/A	N/A	$46.97 per share	0.18
UPXI Upexi	$15.81M	5.25	N/A	N/A	$1.01 per share	1.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HSDT Solana	-$40.89M	-$30.32	N/A	32.64	N/A	-1,302.78%	-41.86%	-18.53%	11/17/2026 (Estimated)
LITS Lite Strategy	-$15.94M	-$1.60	N/A	N/A	N/A	N/A	-90.81%	-89.33%	N/A
NAKA KindlyMD	-$52.23M	-$35.85	N/A	N/A	N/A	-1,067.93%	-63.45%	-41.04%	N/A
UPXI Upexi	-$13.68M	-$0.62	N/A	N/A	N/A	-874.00%	-66.70%	-19.56%	9/24/2026 (Estimated)

Latest LITS, NAKA, HSDT, and UPXI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/24/2026	Q4 2026	UPXI Upexi	-$0.09	N/A	N/A	N/A	$7.00 million	N/A
8/14/2026	Q2 2026	HSDT Solana	-$0.02	-$0.38	-$0.36	-$0.38	$3.50 million	$2.53 million
8/13/2026	Q2 2026	NAKA KindlyMD	N/A	-$6.65	N/A	-$6.65	N/A	$35.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HSDT Solana	N/A	N/A	N/A	N/A	N/A
LITS Lite Strategy	N/A	N/A	N/A	N/A	N/A
NAKA KindlyMD	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HSDT Solana	N/A	13.31	13.31
LITS Lite Strategy	N/A	11.53	11.53
NAKA KindlyMD	N/A	0.15	0.15
UPXI Upexi	2.96	1.72	1.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HSDT Solana	18.63%
LITS Lite Strategy	52.38%
NAKA KindlyMD	N/A
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
HSDT Solana	14.40%
LITS Lite Strategy	1.60%
NAKA KindlyMD	24.49%
UPXI Upexi	9.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HSDT Solana	21	60.46 million	51.75 million	Not Optionable
LITS Lite Strategy	100	34.03 million	33.48 million	N/A
NAKA KindlyMD	N/A	17.90 million	13.51 million	N/A
UPXI Upexi	59	78.70 million	71.62 million	Optionable

LITS, NAKA, HSDT, and UPXI Headlines

Recent News About These Companies

Upexi Q4 Earnings Call Highlights

11 minutes ago | marketbeat.com

Upexi (UPXI) Stock Falls on Quarterly Earnings

2 hours ago | quiverquant.comQ

Upexi Reports Fiscal 2026 Results, Digital Asset Revenue of $17.4 Million and 2.34 Million SOL Held at Year-End

2 hours ago | quiverquant.comQ

Upexi Reports Financial Results for Fiscal Year Ended June 30, 2026

2 hours ago | globenewswire.com

Upexi (UPXI) to Post Quarterly Earnings on Thursday

September 17 at 1:10 AM | americanbankingnews.com

Upexi to Host Fiscal Year 2026 Earnings Call on Thursday, September 17th at 5:30 P.M. ET

September 15 at 8:00 AM | globenewswire.com

Upexi Amends BitGo Credit Facility

September 14 at 8:00 AM | globenewswire.com

Upexi (NASDAQ:UPXI) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

September 12, 2026 | americanbankingnews.com

Upexi (NASDAQ:UPXI) Upgraded at Wall Street Zen

September 12, 2026 | americanbankingnews.com

Wall Street Zen Upgrades Upexi (NASDAQ:UPXI) to "Hold"

September 12, 2026 | marketbeat.com

Cantor Fitzgerald Boosts Upexi (NASDAQ:UPXI) Price Target to $2.00

September 10, 2026 | marketbeat.com

Upexi to Participate in FT Partners FinTech Conference 2026 on September 15th

September 8, 2026 | globenewswire.com

Upexi (UPXI) Expected to Release Earnings on Wednesday

August 26, 2026 | marketbeat.com

Upexi Faces Nasdaq Non-Compliance on Minimum Bid Price

July 31, 2026 | tipranks.com

Upexi Insider Trading Activity | NASDAQ:UPXI | Benzinga

July 7, 2026 | benzinga.com

Upexi Inc: Upexi Partners with Blueprint to Stake Solana Treasury Assets

June 30, 2026 | finanznachrichten.de

Upexi Partners with Blueprint to Stake Solana Treasury Assets

June 30, 2026 | globenewswire.com

Upexi Added to Russell Microcap Index in June 2026 Reconstitution

June 26, 2026 | quiverquant.comQ

Upexi Added to the Russell Microcap® Index

June 26, 2026 | globenewswire.com

Upexi, Inc. Announces Pricing of ~$19.5 Million Private Placement of Common Stock

June 22, 2026 | globenewswire.com

Upexi Shareholders Reelect Board and Ratify Auditor

June 16, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LITS, NAKA, HSDT, and UPXI Company Descriptions

Solana NASDAQ:HSDT

$2.29 -0.01 (-0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$2.29 0.00 (0.00%)

As of 06:36 PM Eastern

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

Lite Strategy NASDAQ:LITS

$1.04 +0.02 (+1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$1.06 +0.01 (+1.44%)

As of 04:10 PM Eastern

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

KindlyMD NASDAQ:NAKA

$8.50 +0.30 (+3.66%)

As of 04:00 PM Eastern

Kindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.

Upexi NASDAQ:UPXI

$1.06 +0.01 (+0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$1.03 -0.02 (-1.90%)

As of 07:07 PM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LITS, NAKA, HSDT, and UPXI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LITS, NAKA, HSDT, and UPXI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LITS, NAKA, HSDT, and UPXI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LITS, NAKA, HSDT, and UPXI Company Descriptions

Solana NASDAQ:HSDT

Lite Strategy NASDAQ:LITS

KindlyMD NASDAQ:NAKA

Upexi NASDAQ:UPXI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LITS, NAKA, HSDT, and UPXI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LITS, NAKA, HSDT, and UPXI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LITS, NAKA, HSDT, and UPXI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LITS, NAKA, HSDT, and UPXI Company Descriptions

Solana NASDAQ:HSDT

Lite Strategy NASDAQ:LITS

KindlyMD NASDAQ:NAKA

Upexi NASDAQ:UPXI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools